logo
Back to Home

Unlocking the Brain's Mood Regulator in Bipolar Disorder

A pioneering scientific collaboration, spearheaded by researchers from the Keck School of Medicine of USC's Stevens Neuroimaging and Informatics Institute, Stanford University, and Johns Hopkins University, has embarked on a critical mission to unravel the biological underpinnings of mood fluctuations in bipolar disorder. With the support of a substantial $4.5 million grant from BD², the team is investigating specialized neurons, dubbed 'retrosplenial switch cells,' located in the retrosplenial cortex. This comprehensive study integrates postmortem single-cell histology, polygenic risk scores from a large patient cohort, and extensive neuroimaging data to illuminate the mechanisms by which this brain region oscillates between states of depression and mania. This endeavor promises to shed light on one of psychiatry's most enduring mysteries and pave the way for more effective therapeutic interventions.

Breakthrough Research Targets Bipolar Mood Switching Mechanism

In a significant stride toward understanding bipolar disorder, a consortium of leading institutions—including the Keck School of Medicine of USC, Stanford University, and Johns Hopkins University—has initiated a three-year research project funded by a $4.5 million Discovery Research grant from Breakthrough Discoveries for thriving with Bipolar Disorder (BD²). The research, announced on October 27, 2026, aims to identify the specific neural mechanisms responsible for the abrupt and often debilitating mood shifts characteristic of bipolar disorder.

Led by Dr. Christopher R.K. Ching, Assistant Professor of Research Neurology at the Stevens Neuroimaging and Informatics Institute, alongside Dr. Laramie Duncan of Stanford and Dr. Fernando Goes of Johns Hopkins, the team is focusing on the retrosplenial cortex (RSC). This region, historically linked to memory and spatial navigation, has recently been implicated in psychiatric conditions. A landmark 2025 study in Nature Neuroscience by Duncan and colleagues highlighted that particular neuronal subtypes within the RSC, now termed 'retrosplenial switch cells,' exhibit genetic vulnerabilities in individuals with bipolar disorder. Researchers hypothesize that these cells act as crucial regulators of mood stability, with their dysfunction potentially triggering manic or depressive episodes.

The ambitious project employs a multi-faceted approach, integrating three distinct scientific layers:

  1. Molecular and Cellular Profiling: High-resolution molecular techniques will be used to map cell populations in postmortem brain tissue from individuals with and without bipolar disorder, identifying unique cellular anomalies.
  2. Genomic Risk and Clinical Trajectories: Leveraging the BD² Integrated Network, a cohort of 4,000 bipolar disorder patients, researchers will assess if polygenic risk scores can predict mood switching frequency and treatment responses.
  3. Macroscale Connectome Neuroimaging: Structural and functional MRI data from the BD² cohort will be analyzed to chart the communication pathways between the retrosplenial cortex and other brain networks, utilizing the global ENIGMA consortium.

Melody Kang, a USC Neuroscience PhD student involved in the project, emphasized the use of advanced brain network modeling approaches developed within the ENIGMA Bipolar Disorder Working Group, directed by Dr. Ching. This global network pools neuroimaging data from over 250 institutions, offering an unprecedented scale for analysis. Dr. Arthur W. Toga, Director of the Stevens INI, underscored the collaborative nature of the project, highlighting how the integration of imaging, genetics, and cell biology across shared data will enhance the probability of finding answers vital to patients. The outcomes of this exploratory research are expected to pinpoint specific molecular pathways within retrosplenial switch cells, forming the foundation for future targeted therapies designed to stabilize mood and improve the lives of those affected by bipolar disorder.

This innovative research initiative represents a pivotal moment in neuropsychiatry. By diving deep into the intricate cellular and genetic mechanisms governing mood switching, scientists are not merely observing symptoms but are striving to uncover the fundamental biological levers that control these shifts. The collaborative, multi-scale approach, embracing cutting-edge technologies and vast datasets, holds immense promise. It offers a tangible pathway towards developing precision treatments that move beyond broad-spectrum mood stabilizers, potentially ushering in an era where bipolar disorder can be managed with unprecedented accuracy and efficacy, thereby significantly enhancing the quality of life for millions worldwide.